Patient-derived Staphylococcus aureus bacterial antigens

Patient-derived Staphylococcus aureus bacterial antigens refer to the unique repertoire of proteins, polysaccharides, and toxins isolated from a specific patient's infecting S. aureus strain. These antigens typically include critical virulence factors such as Staphylococcal Protein A (SpA), Clumping factors (ClfA/B), and Alpha-hemolysin (Hla), which the bacteria use to adhere to host tissues and evade the immune system. In clinical practice, these antigens serve as the active components of autogenous (autologous) vaccines, a form of personalized immunotherapy used to treat chronic or recurrent infections that are resistant to conventional antibiotics. By utilizing the exact antigenic profile of the patient's own isolate, these therapies aim to overcome the significant strain-to-strain variability of S. aureus and elicit a highly targeted immune response. The therapeutic mechanism involves stimulating the host's B-cells and T-cells to produce neutralizing antibodies and activate opsonophagocytic killing by neutrophils, thereby reducing the bacterial burden and preventing disease recurrence. While historically used for conditions like chronic furunculosis and osteomyelitis, these antigens are also being explored in modern contexts such as priming the tumor microenvironment in cancer immunotherapy and managing staphylococcal-driven exacerbations in inflammatory skin diseases.

Other names

Autologous Staphylococcus aureus antigensAutogenous Staphylococcus aureus vaccine antigensPatient-specific S. aureus antigensStaphylococcus aureus autovaccine antigensS. aureus whole-cell antigens

Induction of strain-specific humoral and cellular immune responses, including the production of neutralizing antibodies (IgG) and the activation of opsonophagocytic pathways to eliminate the specific infecting bacterial strain.